The metabolic signature of cardiorespiratory fitness: a protocol for a systematic review and meta-analysis

Justin Carrard, Chiara Guerini, Christian Appenzeller-Herzog, Denis Infanger, Karsten Königstein, Lukas Streese, Timo Hinrichs, Henner Hanssen, Hector Gallart-Ayala, Julijana Ivanisevic, Arno Schmidt-Trucksass

ABSTRACT

Introduction A low cardiorespiratory fitness (CRF) is a strong and independent predictor of cardiometabolic, cancer and all-cause mortality. To date, the mechanisms linking CRF with reduced mortality remain largely unknown. Metabolomics, which is a powerful metabolic phenotyping technology to unravel molecular mechanisms underlying complex phenotypes, could elucidate how CRF fosters human health.

Methods and analysis This study aims at systematically reviewing and meta-analysing the literature on metabolites of any human tissue sample, which are positively or negatively associated with CRF. Studies reporting estimated CRF will not be considered. No restrictions will be placed on the metabolomics technology used to measure metabolites. PubMed, Web of Science and EMBASE will be searched for relevant articles published until the date of the last search. Two authors will independently screen full texts of selected abstracts. References and citing articles of included articles will be screened for additional relevant publications. Data regarding study population, tissue samples, analytical technique, quality control, data processing, metabolites associated to CRF, cardiopulmonary exercise test protocol and exercise exhaustion criteria will be extracted. Methodological quality will be assessed using a modified version of QUADOMICS. Narrative synthesis as well as tabular/charted presentation of the extracted data will be included. If feasible, meta-analyses will be used to investigate the associations between identified metabolites and CRF. Potential sources of heterogeneity will be explored in meta-regressions.

Ethics and dissemination No ethics approval is required. The results will be published in a peer-reviewed journal and as conference presentation.

PROSPERO registration number CRD42020214375.

INTRODUCTION

Cardiorespiratory fitness (CRF), defined as the maximal oxygen uptake, is considered to be such a powerful health marker that the American Heart Association recommends assessing it as a vital sign in clinical routine. Indeed, CRF has been inversely correlated with incidence of cancer, cardiometabolic diseases as well as with all-cause mortality. Even more importantly, improvement in CRF is associated with reduced incidence of stroke, type 2 diabetes, dementia and lowered all-cause mortality.

CRF reflects the capacity of the body to transport oxygen from its uptake in the air to its delivery to the mitochondria in order to carry out physical work. If the heritability of both CRF and gains in CRF has been shown to be around 50%, the biological mechanisms linking CRF with reduced morbidity and mortality remain largely unknown. Since CRF is considered a better morbidity and mortality predictor than physical activity level itself, it can be deduced that the mechanisms underlying responses to exercise are not sufficient to explain the link between CRF and mortality. Understanding through which metabolic pathways CRF mitigates morbidity and mortality might pave the way for novel fitness-enhancing strategies in clinical routine.

Metabolomics is a powerful metabolic phenotyping technology to investigate biochemical mechanisms underlying complex phenotypes. Indeed, the metabolome...
Open access

Table 1 The Population, Exposure, Comparison, Outcome, Study design process

| Item                                             | Specification                                                                 |
|--------------------------------------------------|-------------------------------------------------------------------------------|
| Population or participants and conditions of interest | Humans (any age, any sex and any health condition).                           |
| Exposure                                         | Metabolites derived from metabolomics or multiomics studies applying metabolomics approaches. |
| Comparisons or control groups                    | NA                                                                            |
| Outcomes of interest                             | CRF measured by means of a cardiopulmonary exercise test (spiroergometry).    |
| Study designs                                    | Any study design, only published studies, no editorials, letters, reviews, meta-analyses, case reports or conference abstracts. |

CRF, cardiorespiratory fitness; NA, not available.

readout offers a sensitive and dynamic measure of phenotypes at the molecular level, reflecting the underlying biochemical activity in different physiological conditions or following the exposure to diverse external or internal stimuli.21 22 In contrast to genomics and proteomics, metabolomics provides insights on what has happened.21 The changes recorded in the metabolome reflect the influence of both, the genome and the exposome.21 In addition to having a structural function as building blocks of cell components and fuels in cellular energetics, metabolites are important signalling molecules and a potential driving force in the pathophysiology of human diseases.23 24

Why is it important to do this review?

In the light of the high clinical relevance of CRF, it is of utmost importance to better understand the mechanisms linking CRF with reduced morbidity and mortality. Reviewing and meta-analysing the literature to identify metabolites associated with high and low CRF levels represents a first step to reveal biological mechanisms connecting CRF to health benefits.

Aim and review question

This study aims at systematically reviewing and meta-analysing the current literature on metabolites in human body tissues, fluids, or excretions that are positively or negatively associated with CRF.

The research question of this review is the following: which metabolites in human body tissues, fluids or excretions are positively or negatively associated with CRF?

METHODS AND ANALYSIS

This systematic review protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.25 The initial preliminary search was conducted on 17 August 2020. The protocol was submitted for registration in International Prospective Register of Systematic Reviews on 14 October 2020 and registered on 14 November 2020. The anticipated completion date is 1 November 2021. The research question was formulated according to the Population, Exposure, Comparison, Outcome, Study Type framework (table 1).26

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Eligibility criteria

Inclusion criteria

► All clinical studies involving humans, which were published until the date of the last search.
► Metabolomics studies, or multiomics studies applying metabolomics approaches, reporting metabolites of any tissue, associated, positively or negatively, with CRF.
► Studies measuring CRF by means of a cardiopulmonary exercise test (spiroergometry).

Exclusion criteria

► Studies reporting estimated CRF.
► Studies published in languages other than English, German, French, Italian and Spanish.
► Non-original articles (ie, editorials, letters, reviews), meta-analyses, case reports, conference abstracts.

Methodological considerations

Due to the fact that estimated CRF has been shown to be only moderately correlated with measured CRF studies reporting estimated CRF will not be considered.27

Information sources and search strategy

Search strategies were developed in collaboration with an information specialist (CA-H) using the Peer Review of Electronic Search Strategies framework.28 PubMed, Web of Science and EMBASE will be searched. Database-specific subject headings and text word synonyms around the concepts metabolomics and CRF will be used. The searches will be rerun immediately prior to the final analysis. Search results will be exported to EndNote X9 (Clarivate, London, UK) and deduplicated. The detailed search strings can be found in online supplemental document.
Outcome and prioritisation
The main outcome will be:
- Metabolites which are either positively or negatively associated with measured CRF.

Risk of bias in individual studies
The quality of the following metabolomics workflow key steps will be assessed at the study level: sample collection and storage, sampling time and nutritional protocol before sampling, metabolite extraction method, analytical technique, quality control used to assess data quality, data processing and metabolite annotation. Additionally, a custom modified version of QUADOMICS will be used for study quality rating (online supplemental table S1) 29,30 The risk of bias at the study level will be assessed by two authors independently (CG and JC). Discrepancies will be resolved through discussion (with a third party if necessary, LS).

Data synthesis
Data issued from untargeted (relative quantification) and targeted (absolute quantification) metabolomics studies will be analysed separately. 31 Quantitative data describing associations between metabolites and CRF levels will be extracted from all selected studies. The data will be presented in tabular/charted format. The adequate summary measure will be determined according to the nature of the collected outcomes (likely correlation or regression coefficients). 32 Effect sizes will be converted into the chosen summary measure as previously described. 33

In case of longitudinal data, information available for several time points will be extracted, too. Only metabolites, which are reported in at least three different studies and are identified on a level 1 identification according to the Metabolomics Standards Initiative, will be meta-analysed. 34 In other words, three data points will be the minimum threshold for conducting a meta-analysis.

Summary measures will be calculated using a random effects model. Restricted maximum likelihood will be used to estimate between-study variance. 35 Forest plots will be used to display and compare estimates across studies. Heterogeneity among studies will be estimated by the Cochran Q test and quantified by the 1 statistic. 36

Additional analyses
Potential sources of heterogeneity will be explored in meta-regressions, such as age, sex, health conditions and physical activity levels, study design (case-control, nested case-control, cohort), biological sample and analytical technique (gas or liquid chromatography coupled with mass spectrometry; or proton nuclear magnetic resonance).

Meta-bias(es)
If at least five studies report on the same outcome parameter, publication bias will be assessed using funnel plots, displaying effect estimates against sample sizes. 37 Plot asymmetry will be assessed using Egger’s regression test,
where a regression intercept of zero indicates an absence of publication bias.

Confidence in cumulative evidence
The confidence in evidence will be evaluated with the Grading of Recommendations Assessment, Development and Evaluation system, which is a tool classifying evidence into one of four categories ranging from very low to high. 38

Ethics and dissemination
The present work is a systematic review and meta-analysis protocol. No human participants will be involved; therefore, no ethics approval is required. It is planned to communicate the study results in a peer-reviewed journal and as a conference presentation.

CONCLUSION
The biological mechanisms linking CRF with reduced morbidity and all-cause mortality remain largely unknown. Conducting a systematic review to identify metabolites associated, positively or negatively, with CRF could be a first step to reveal metabolic pathways mediating the protective effect of high CRF level. Finally, understanding through which pathways CRF mitigates morbidity and mortality might pave the way for novel fitness-enhancing strategies in clinical routine.

REFERENCES
1 Ross R, Blair SN, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American heart association. Circulation 2016;134:e653–99.
2 Ahmed HM, Al-Mallah MH, McEvoy JW, et al. Maximal exercise testing variables and 10-year survival: fitness risk score derivation from the fit project. Mayo Clin Proc 2015;90:346–55.
3 Robsahm TE, Falk RS, Heir T, et al. Measured cardiorespiratory fitness and self-reported physical activity; associations with cancer risk and death in a long-term prospective cohort study. Cancer Med 2016;5:2136–44.
4 Farrell SW, Finley CE, Radford NB, et al. Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper center longitudinal study. Circ Heart Fail 2013;6:898–905.
5 Gander JC, Sui X, Hibbert JR, et al. Association of cardiorespiratory fitness with coronary heart disease in asymptomatic men. Mayo Clin Proc 2015;90:1372–9.
6 Juraschek SP, Blaha MJ, Whelton SP, et al. Physical fitness and hypertension in a population at risk for cardiovascular disease: the Henry Ford exercise testing (fit) project. J Am Heart Assoc 2014;3:e001268.
7 Williams PT. Changes in vigorous physical activity and incident diabetes in male runners. Diabetes Care 2007;30:2838–42.
8 Prestgaard E, Mariampillai J, Engeseth K, et al. Change in cardiorespiratory fitness and risk of stroke and death. Stroke 2018;Strokea118021798.
9 de Lannoy L, Sui X, Lavié CJ, et al. Change in submaximal cardiorespiratory fitness and all-cause mortality. Mayo Clin Proc 2018;93:184–90.
10 Tarp J, Stoile AP, Blond K, et al. Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetologia 2019;62:1129–42.
11 Ehrman JK, Brawner CA, Al-Mallah MH, et al. Cardiorespiratory fitness change and mortality risk among black and white patients: Henry Ford exercise testing (FIT) project. Am J Med 2017;130:1177–83.
12 Tari AR, Nauman J, Zisko N, et al. Temporal changes in cardiorespiratory fitness and risk of dementia incidence and mortality: a population-based prospective cohort study. Lancet Public Health 2019;4:e565–74.
13 Imboden MT, Harber MP, Whaley MH, et al. The association between the change in directly measured cardiorespiratory fitness across time and mortality risk. Prog Cardiovasc Dis 2019;62:157–62.
14 Bouchard C, Daw EW, Rice T, et al. Familial resemblance for VO2max in the sedentary state: the heritage family study. Med Sci Sports Exerc 1998;30:252–8.
15 Bouchard C, Sarzynski MA, Rice TK, et al. Genomic predictors of the maximal O2 uptake response to standardized exercise training programs. J Appl Physiol 2011;110:1160–70.
16 Ross R. Knowing that cardiorespiratory fitness should be a vital sign is not enough. Mayo Clin Proc 2019;94:1395–7.
17 Williams PT. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc 2001;33:754–61.
18 Myers J, Kaykha A, George S, et al. Fitness versus physical activity patterns in predicting mortality in men. Am J Med 2004;117:912–8.
19 Lee D-C, Sui X, Ortega FB, et al. Comparisons of leisure-time physical activity and cardiorespiratory fitness as predictors of all-cause mortality in men and women. Br J Sports Med 2011;45:504–10.
20 Sanford JA, Nogiec CD, Lindholm ME, et al. Molecular transducers of physical activity Consortium (MoTPAC): mapping the dynamic responses to exercise. Cell 2020;181:1464–74.
21 Ivanisevic J, Thomas A. Metabolomics as a Tool to Understand Pathophysiological Processes. In: Giera M, ed. Clinical metabolomics: methods and protocols. New York, NY: Springer New York, 2018: 3–28.
22 Hoffman JM, Lyu Y, Pletcher SD, et al. Proteomics and metabolomics in aging research: from biomarkers to systems biology. Essays Biochem 2017;61:379–88.
23 Rinschen MM, Ivanisevic J, Giera M, et al. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol 2019;20:352–67.
24 Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev 2019;99:1819–75.
25 Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
26 Methley AM, Campbell S, Chew-Graham C, et al. PICO, PICOS and spider: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res 2014;14:579.
27 Loprinzi PD, Edwards MK, Addoh O, et al. Evaluation of the convergent validity of an estimated cardiorespiratory fitness algorithm. Eur J Appl Physiol 2018;118:629–36.
28 McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol 2016;75:40–6.
29 Lumbiras B, Porta M, Márquez S, et al. QUADOMICS: an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of ‘omics’-based technologies. Clin Biochem 2008;41:1316–25.
30 Parker LA, Gómez Saez N, Lumbiras B, et al. Methodological deficits in diagnostic research using ‘omics’ technologies: evaluation of the QUADOMICS tool and quality of recently published studies. PLoS One 2010;5:e11419.
31 Lu W, Su X, Klein MS, et al. Metabolite measurement: pitfalls to avoid and practices to follow. Annu Rev Biochem 2017;86:277–304.
32 Borenstein M, Hedges LV, Higgins JPT, et al. Effect sizes based on correlations. In: Introduction to Meta-Analysis, 2009: 41–3.
33 Borenstein M, Hedges LV, Higgins JPT, et al. Converting among effect sizes. In: Introduction to Meta-Analysis, 2009: 45–9.
34 Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis chemical analysis Working Group (CAWG) metabolomics standards initiative (MSI). Metabolomics 2007;3:211–21.
35 Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods 2019;10:83–98.
36 Borenstein M, Hedges LV, Higgins JPT. Introduction to meta-analysis. John Wiley & Sons, 2011.
37 Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001;54:1046–55.
38 Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.